[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontal-bone-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontal-bone-loss":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,77,101,120,152,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100639400","polynucleotides-and-hyaluronic-acid-vs-enamel-matrix-proteins-in-the-treatment-of-intrabony-defects-100639400",false,"NCT07589959","Polynucleotides and Hyaluronic Acid vs Enamel Matrix Proteins in the Treatment of Intrabony Defects","Polynucleotides and Hyaluronic Acid vs Enamel Matrix Derivative Proteins in the Treatment of Intrabony Defects: A Randomized Controlled Clinical Trial","PN-HAVSEMPIND","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Non-smokers or light smokers (fewer than 10 cigarettes per day)\n* No diabetes or well-controlled diabetes\n* At least one infrabony periodontal defect ≥ 3 mm in depth\n* Periodontal pocket depth ≥ 6 mm at baseline (after initial treatment)\n* Full-mouth plaque and bleeding scores ≤ 20%, ≤15% at re-evaluation\n* Ability and willingness to attend follow-up visits for 1, 3, and 5 years\n* Teeth included in the study must be healthy from an endodontic point of view or properly root-treated\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients with weakened immune systems or significant systemic diseases\n* Heavy smokers (more than 10 cigarettes per day)\n* Full-mouth plaque or bleeding scores \\>20%, \\>15%\n* Current alcohol or drug abuse\n* Patients who have received periodontal treatment within the last 6 months\n* Patients unwilling or unable to attend follow-up visits required for the study","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare two periodontal regenerative treatments in adults with Stage III or IV periodontitis and infrabony periodontal defects ≥3 mm.\n\nThe study aims to determine whether hyaluronic acid and polynucleotides (Regenfast®) combined with bovine bone graft material (Bio-Oss®) provides similar or improved periodontal regeneration compared with enamel matrix derivative proteins (Emdogain®) combined with Bio-Oss®.\n\nResearchers will evaluate:\n\n* Periodontal healing and bone regeneration\n* Changes in probing depth, clinical attachment level, gingival recession, and tooth mobility\n* Radiographic bone fill\n* Survival of treated teeth after 1, 3, and 5 years\n\nParticipants will:\n\n* Receive initial periodontal treatment and oral hygiene instruction\n* Undergo clinical and radiographic evaluation\n* Receive minimally invasive periodontal regenerative surgery under local anesthesia\n* Be randomly assigned to receive either Regenfast® + Bio-Oss® or Emdogain® + Bio-Oss®\n* Attend follow-up visits with periodontal examinations and radiographs over 5 years",[27,28,29,30],"Periodontal Bone Loss","Periodontal Defect","Periodontitis Stage III","Periodontitis Stage IV",[32,33,34,35],"Infrabony Periodontal Defects","Polynucleotides","Hyaluronic Acid","Enamel Matrix Proteins","NOT_YET_RECRUITING","2026-05-11",{"date":39,"type":40},"2026-05-15","ACTUAL",{"date":42,"type":21},"2026-05",{"date":44,"type":21},"2031-07-30",{"name":46,"class":47},"Shashi Dadlani","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100624152","3d-printed-customized-bone-graft-for-alveolar-regeneration-longitudinal-cohort-evaluation-100624152","NCT07405918","3D Printed Customized Bone Graft for Alveolar Regeneration: Longitudinal Cohort Evaluation","Inclusion Criteria:\n\n* Systemically healthy individuals\n* over 18 years of age\n* Subjects that received regenerative surgical treatment by customized 3D printed blocks.\n* Subjects must agree to participate in the study and agree to sign the Informed Consent.\n\nExclusion Criteria:\n\n* Subjects with ilness that avoid their presence to the clinical evaluation\n* ISubjects who have lost the customized blocks\n* Subjects who do not agree to participate in the study will be excluded.",true,"15 Years",{"count":57,"type":21},100,"6 Years","OBSERVATIONAL","This study will evaluate the behavior of the implant-supported restorations (prosthesis) placed into the areas grafted with the 3D printed customized bone (personalized graft produced to fit a specific bone defect), as well as the volume contraction of the printed bone.",[62,27],"Periodontal Diseases",[64,65,66,67],"Personalized bone graft","3D printed customized bone block","Guided Bone Regeneration","Personalized Medicine","2026-04-26",{"date":70,"type":40},"2026-04-28",{"date":72,"type":21},"2026-05-01",{"date":74,"type":21},"2026-12-01",{"name":76,"class":47},"University of Guarulhos",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100480249","periodontal-granulation-tissue-preservation-in-surgical-periodontitis-treatment-100480249","NCT05533528","Periodontal Granulation Tissue Preservation in Surgical Periodontitis Treatment","Periodontal Granulation Tissue Preservation in Surgical Periodontal Disease Treatment. A Randomized Clinical Trial","Inclusion Criteria:\n\n* Stage III or IV periodontitis, including all grades.\n* Unresolved deep pockets (probing pocket depth \\[PPD\\] \\>5 mm + BoP) 4 to 6 weeks after non-surgical treatment.\n* Interproximal plaque index \\\u003C35% maintained during periodontal treatment and maintenance.\n* Adherence to periodontal maintenance appointments.\n\nExclusion Criteria:\n\n* Systemic disease contraindicating periodontal surgery.\n* Teeth with incorrect endodontic treatment or restoration.\n* Stage I or II periodontitis.",{"count":85,"type":21},25,[24],"The objective of this study will be to evaluate a new protocol for the surgical treatment of periodontal disease with two novelties: to make a single incision in the midline of the interproximal area to respect the vascular supply and preserve the granulation tissue with regenerative potential.\n\nThe investigators will carry out a controlled and randomized clinical trial with a control group (n=25; modified Kirkland flap) and a test group (n=25; experimental surgical protocol: incision in the mid-interproximal area of the papilla and preservation of the granulation tissue).\n\nClinical parameters will be taken at the time of surgery and 12 months follow-up: bleeding on probing (BoP), clinical attachment level (CAL), residual probing depth (rPD),Probing pocket depth reduction (PPDr), recession (REC), interproximal gingival recession (iGR), width of keratinized gingiva (KT), gain of supra-alveolar clinical attachment (SUPRA-AG), early wound healing index (EHI).",[89,62,27],"Periodontal Pocket","RECRUITING","2026-02-16",{"date":93,"type":40},"2026-02-19",{"date":95,"type":40},"2022-05-03",{"date":97,"type":21},"2027-02-01",{"name":99,"class":47},"Universidad de Murcia",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":100},"100362314","non-incised-papillae-surgical-approach-nipsa-and-connective-tissue-graft-plus-emdogain-for-periodontal-defects-100362314","NCT03997578","Non-incised Papillae Surgical Approach (NIPSA) and Connective Tissue Graft Plus Emdogain for Periodontal Defects","Non-incised Papillae Surgical Approach (NIPSA) and Connective Tissue Graft Plus Enamel Matrix Derivated and Xenograft for the Treatment of Periodontal Defects: A Controlled Clinical Trial","Inclusion Criteria:\n\n* patients diagnosed with periodontitis.\n* plaque index and bleeding index of \\\u003C 30%.\n* periodontal lesions with pocket probing depth \\> 5 mm.\n* intrabony defect \\> 3 mm.\n* intrabony defect configuration including a 1 and\u002For 2-wall component, always involving the buccal wall.\n\nExclusion Criteria:\n\n* patients with systemic diseases that contraindicated treatment.\n* third molars.\n* teeth with incorrect endodontic or restorative treatment.",{"count":20,"type":21},[24],"The present study pretends to show the results of combining a modification of the Non-incised papillae surgical approach (NIPSA) attempting to improve the outcome in the treatment of teeth with advanced periodontal support loss.",[112,27,113],"Periodontitis","Periodontal; Lesion",{"date":93,"type":40},{"date":116,"type":40},"2019-09-03",{"date":118,"type":21},"2027-02-02",{"name":99,"class":47},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":129,"conditions":130,"keywords":136,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":100},"100612479","the-role-of-granulation-tissue-in-periodontal-regeneration-100612479","NCT07254117","The Role of Granulation Tissue in Periodontal Regeneration","The Role of Biochemical and Microbiological Properties of Granulation Tissue in Periodontal Regeneration","Inclusion Criteria:\n\n1. Both genders.\n2. Systemically healthy.\n3. Both smokers (smoking at least 10 cigarettes a day or electronic cigarettes daily or quit less than 5 years ago) and non-smokers (never smoked, smoke no more than once a month or quit at least 5 years ago).\n4. Patients aged 18 years and over.\n5. Patients with a history of severe periodontitis (stage III or IV, grade B-C) and, after completion of the non-surgical stage of periodontal treatment with at least one residual vertical bone defects (with ≥3 mm infrabony component) in premolar-molar region.\n6. Patients with a plaque index and bleeding on probing of 20% or lower before surgery.\n\nExclusion Criteria:\n\n1. Systemic diseases that may affect study results (uncontrolled type 2 diabetes mellitus (HBA1c level of \\>7%); recent (less than 6 months ago) myocardial infarction or stroke; blood coagulation disorders; recent use of antibiotics (less than 6 months).\n2. Use of medications that may affect study results (anti-osteoporotic drugs, statins, corticosteroids, calcium channel blockers, cyclosporine A, antiepileptic drugs, antipsychotic medication or antidepressants, chemotherapy and\u002For radiotherapy (active or history)).\n3. Current pregnancy and\u002For breastfeeding.\n4. Patients who have received any form of systemic antibiotics in the last six months prior to the start of the study.\n5. Patients who require antibiotic premedication prior to periodontal treatment.\n6. Prosthetic factors in teeth associated with suitable bone defects that prevent clinical measurements.\n7. Lack of patient motivation to undertake adequate dental care at home or to complete periodontal treatment.\n8. Strong vomiting reflex preventing adequate periodontal treatment.",{"count":128,"type":21},46,"The goal of this observational study is to distinguish the infectious, healing, and regeneration-related characteristics of two types of gingival granulation tissues, namely infra-osseous and supra-osseous granulation tissues, in people with severe periodontitis (gum disease). Researchers aim to denote if these tissues may play role in healing after periodontal treatment. Researchers will also compare smokers and non-smokers to see if smoking disrupts the healing potential or infectious properties of granulation tissue. Participants will provide gingival fluid (before) and granulation tissue samples (at the time of) periodontal surgery. The main questions this study aims to answer are: 1. Do infra- and supra-osseous granulation tissues have different healing potential and infectious properties? 2. How do these tissues differ in people who smoke compared to people who do not smoke?",[27,112,131,62,132,133,134,135],"Periodontal Disease","Periodontal Regeneration","Periodontal Granulation Tissue","Vertical Periodontal Bone Defects","Periodontal Healing",[137,112,138,139,140,141,142],"Periodontal granulation tissue","Vertical periodontal bone defects","Vertical defects","Granulation tissue","Periodontal regeneration","Periodontal healing","2025-11-19",{"date":145,"type":40},"2025-11-28",{"date":147,"type":40},"2025-05-29",{"date":149,"type":21},"2026-09",{"name":151,"class":47},"Riga Stradins University",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":100},"100604227","treatment-of-intrabony-defects-with-injectable-platelet-rich-fibrin-and-xenogenic-grafts-100604227","NCT07146776","Treatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts","Evaluation of the Effect of Injectable Platelet-Rich Fibrin in the Treatment of Periodontal Intrabony Defects With Xenogenic Grafts: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Male and female patients aged 18-65 years\n* Patients with Stage III Periodontitis according to the AAP-EFP 2017 Periodontal Disease Classification\n* PPD≥5 mm (if persistent 6 weeks after initial periodontal treatment)\n* Intrabony defects in the interproximal region with 2 or 3 walls and a depth of at least ≥3 mm\n* Non-smokers (those who smoke up to 10 per day may be included)\n\nExclusion Criteria:\n\n* Patients under 18 years of age or older than 65 years of age\n* Patients unable to consent\n* Systemic diseases that could affect the success of surgery, such as uncontrolled diabetes\n* Single-walled intrabony defects\n* Those who have taken antibiotics, anti-inflammatory or immunosuppressive drugs, or birth control pills within the three months prior to the study\n* Those who have received active periodontal treatment within the last six months and periodontal surgery within the last year\n* Smoking more than 10 cigarettes per day\n* Pregnancy or breastfeeding\n* Those taking medications that affect the gums (e.g., calcium channel blockers, phenytoin or cyclosporine)\n* Teeth with furcation defects\n* Those undergoing active orthodontic treatment\n* Those who are allergic to the biomaterials used in the study or prescribed medications","65 Years",{"count":161,"type":21},16,[24],"The use of injectable platelet-rich fibrin (i-PRF) in both surgical and non-surgical dental treatments has become increasingly widespread. Hard tissue grafts can produce \"sticky bone,\" and bone gain can have a positive effect on intrabony defects frequently seen in periodontal disease, compared to grafts alone. This study aims to clinically and radiographically evaluate the effectiveness of using bovine-derived xenogenic bone grafts in combination with i-PRF and bovine-derived xenogeneic bone grafts alone in patients with intrabony defects and stage III periodontitis.",[112,165,62,28,27],"Intrabony Periodontal Defect",[167,168,169,170,171,172],"i-prf","injectable prf","injectable platelet rich fibrin","xenogenic graft","xenogenic bone graft","xenograft","2025-08-31",{"date":175,"type":40},"2025-09-08",{"date":177,"type":40},"2025-07-12",{"date":179,"type":21},"2026-07-01",{"name":181,"class":47},"Saglik Bilimleri Universitesi",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":100},"100587236","effect-of-nitroglycerin-hydrogel-on-repairing-critical-bone-defects-100587236","NCT06925763","Effect of Nitroglycerin Hydrogel on Repairing Critical Bone Defects","Unlocking the Regenerative Potential: The Effect of Nitroglycerin Hydrogel on Repairing Critical Bone Defects (Experimental Study)","Nitro- Bone","Inclusion Criteria:\n\n* All animals were adult with an age ranging between 3 to 7 months and a weight ranging between 250 and 350 g\n\nExclusion Criteria:\n\n* other than inclusion","7 Months",{"count":192,"type":21},33,[24],"Due to their osteoconductive, osteoinductive, and osteogenic qualities, autologous bone grafts are the gold standard for augmenting bone, (1). However, problems, insufficient bone quantity, and\u002F or quality at the donor location could prevent it from being used. Consequently, a variety of bone graft materials, such as allografts and\u002For xenografts, were developed to improve bone development and provide an osteoconductive matrix in the so-called hard tissue critical-size defect (CSD) (2).\n\n\"critically-sized\" defect is regarded as one that would not heal spontaneously despite surgical stabilization and requires further surgical intervention (3). The management of critical-sized bone defects remains a major clinical orthopedic challenge. Critical-sized bone defects are technically defined as those that will not heal spontaneously during the patient's lifetime. Bone loss greater than 2 times the diameter of the long bone diaphysis is unlikely to result in union despite appropriate stabilization methods (4).\n\nNitroglycerin, also known as glyceryl trinitrate (GTN), is a medication commonly used to treat heart conditions like angina pectoris and chronic heart failure. It acts as a potent vasodilator, dilating the vascular system to improve blood flow. Nitroglycerin has been found to have a positive effect on bone formation. Studies indicate that Nitroglycerin when applied topically, can increase bone formation and reduce bone resorption. This effect is achieved through the stimulation of osteoblastic differentiation and proliferation (5).\n\nThe mechanism of action of Nitroglycerin in bone formation involves its conversion into nitric oxide (NO), which plays a crucial role in stimulating bone formation. Nitric oxide released from nitroglycerin acts as a signaling molecule that enhances osteoblastic differentiation and proliferation of bone marrow-derived mesenchymal stem cells. This process leads to increased bone mineral density, improved bone geometry, and enhanced bone strength (5).\n\nHydrogels are natural or synthetic biocompatible polymers that are widely used in periodontal tissue engineering as a delivery material for different biologics (6). Synthetic hydrogels have superiority in chemical and mechanical properties over natural hydrogels (7). Carbopol or polyacrylic acid (PAA) is one of the most widely used polymers as a hydrogel. It is an anionic polyelectrolyte that can be readily polymerized and crosslinked to form hydrogels with a swelling capacity greater than their dry weight (8).",[196,27,197],"Bone Regeneration","Healing Fracture of Bone",[199,200,201],"nitroglycerin,","bone regeneration","critical size defect","2025-04-07",{"date":204,"type":40},"2025-04-13",{"date":206,"type":21},"2025-04-01",{"date":208,"type":21},"2025-08-01",{"name":210,"class":47},"Minia University"]